These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 17936869)

  • 21. Large-scale expression and purification of the major HIV-1 coreceptor CCR5 and characterization of its interaction with RANTES.
    Nisius L; Rogowski M; Vangelista L; Grzesiek S
    Protein Expr Purif; 2008 Oct; 61(2):155-62. PubMed ID: 18588983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism.
    Raymond S; Delobel P; Mavigner M; Cazabat M; Souyris C; Sandres-Sauné K; Cuzin L; Marchou B; Massip P; Izopet J
    AIDS; 2008 Sep; 22(14):F11-6. PubMed ID: 18753930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry.
    Safarian D; Carnec X; Tsamis F; Kajumo F; Dragic T
    Virology; 2006 Sep; 352(2):477-84. PubMed ID: 16777164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and evaluation of potential inhibitors of HIV gp120-CD4 interactions.
    Boussard C; Klimkait T; Mahmood N; Pritchard M; Gilbert IH
    Bioorg Med Chem Lett; 2004 May; 14(10):2673-6. PubMed ID: 15109676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays.
    Van Baelen K; Vandenbroucke I; Rondelez E; Van Eygen V; Vermeiren H; Stuyver LJ
    J Virol Methods; 2007 Dec; 146(1-2):61-73. PubMed ID: 17640743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Buffering deleterious polymorphisms in highly constrained parts of HIV-1 envelope by flexible regions.
    Gasser R; Hamoudi M; Pellicciotta M; Zhou Z; Visdeloup C; Colin P; Braibant M; Lagane B; Negroni M
    Retrovirology; 2016 Jul; 13(1):50. PubMed ID: 27473399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations.
    Platt EJ; Durnin JP; Shinde U; Kabat D
    J Mol Biol; 2007 Nov; 374(1):64-79. PubMed ID: 17920626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific interaction of CXCR4 with CD4 and CD8alpha: functional analysis of the CD4/CXCR4 interaction in the context of HIV-1 envelope glycoprotein-mediated membrane fusion.
    Basmaciogullari S; Pacheco B; Bour S; Sodroski J
    Virology; 2006 Sep; 353(1):52-67. PubMed ID: 16808956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development.
    Kadow J; Wang HG; Lin PF
    Curr Opin Investig Drugs; 2006 Aug; 7(8):721-6. PubMed ID: 16955683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
    Seto M; Aikawa K; Miyamoto N; Aramaki Y; Kanzaki N; Takashima K; Kuze Y; Iizawa Y; Baba M; Shiraishi M
    J Med Chem; 2006 Mar; 49(6):2037-48. PubMed ID: 16539392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge.
    Repits J; Sterjovski J; Badia-Martinez D; Mild M; Gray L; Churchill MJ; Purcell DF; Karlsson A; Albert J; Fenyö EM; Achour A; Gorry PR; Jansson M
    Virology; 2008 Sep; 379(1):125-34. PubMed ID: 18672260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV coreceptor phenotyping in the clinical setting.
    Low AJ; Swenson LC; Harrigan PR
    AIDS Rev; 2008; 10(3):143-51. PubMed ID: 18820716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
    Auwerx J; François KO; Covens K; Van Laethem K; Balzarini J
    Virology; 2008 Dec; 382(1):10-9. PubMed ID: 18930512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular characterization of the env gene of two CCR5/CXCR4-independent human immunodeficiency 2 primary isolates.
    Santos-Costa Q; Parreira R; Moniz-Pereira J; Azevedo-Pereira JM
    J Med Virol; 2009 Nov; 81(11):1869-81. PubMed ID: 19774680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions.
    McFadden K; Cocklin S; Gopi H; Baxter S; Ajith S; Mahmood N; Shattock R; Chaiken I
    Proteins; 2007 May; 67(3):617-29. PubMed ID: 17348010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes.
    Garrido C; Roulet V; Chueca N; Poveda E; Aguilera A; Skrabal K; Zahonero N; Carlos S; García F; Faudon JL; Soriano V; de Mendoza C
    J Clin Microbiol; 2008 Mar; 46(3):887-91. PubMed ID: 18199789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition.
    Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM
    Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV pseudovirion vaccine exposing Env "fusion intermediates"-response to immunisation in human CD4/CCR5-transgenic rats.
    Bosch V; Pfeiffer T; Devitt G; Allespach I; Ebensen T; Emerson V; Guzman CA; Keppler OT
    Vaccine; 2009 Apr; 27(16):2202-12. PubMed ID: 19428834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a chemokine receptor CCR5-negative T cell line and its use in determining human immunodeficiency virus type 1 phenotype.
    Binninger-Schinzel D; Müller D; Wolf T; Krause B; Meye B; Winskowsky G; Raupp S; Norley S; Brodt R; Werner A
    J Med Virol; 2008 Feb; 80(2):192-200. PubMed ID: 18098144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.